4DMT To Present Interim Data From Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial For Cystic Fibrosis At 2023 NACFC
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics (NASDAQ:FDMT) announced that interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC). The company will also host a live webcast to discuss the data in detail and provide a program update. The interim data will include additional safety and clinical activity follow-up on Cohort 1 and initial safety and biomarker data from Cohort 2.
October 25, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
4D Molecular Therapeutics' announcement of presenting interim data from its Phase 1/2 AEROW clinical trial at the 2023 NACFC could potentially impact its stock positively, as it indicates progress in their clinical trials.
The announcement of presenting interim data from a clinical trial is generally seen as a positive development, as it indicates progress in the trial. This could potentially lead to increased investor confidence in the company, which could positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100